roxatidine acetate has been researched along with Gastroduodenal Ulcer in 11 studies
roxatidine acetate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "Roxatidine acetate is a histamine H2-receptor antagonist which, after almost complete oral absorption (greater than 95%), is rapidly converted to its active metabolite, roxatidine, by esterases in the small intestine, plasma and liver." | 6.38 | Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. ( McTavish, D; Murdoch, D, 1991) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The effects of a new H2-receptor antagonist, roxatidine acetate, have been investigated in both clinical and pharmacodynamic trials in Europe and the United States." | 2.66 | Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials. ( Bender, W; Labs, R; Merki, HS, 1989) |
| "Roxatidine acetate is a histamine H2-receptor antagonist which, after almost complete oral absorption (greater than 95%), is rapidly converted to its active metabolite, roxatidine, by esterases in the small intestine, plasma and liver." | 2.38 | Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. ( McTavish, D; Murdoch, D, 1991) |
| " Relationships between pharmacokinetic variables and each parameter related to hepatic functions were also investigated." | 1.31 | Pharmacokinetics of roxatidine acetate in patients with chronic liver disease. ( Takase, S; Tsutsumi, M; Ueshima, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Umegaki, E | 1 |
| Yoda, Y | 1 |
| Tokioka, S | 1 |
| Murano, M | 1 |
| Higuchi, K | 1 |
| Dammann, HG | 1 |
| Wolf, N | 1 |
| Burkhardt, F | 1 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 1 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 1 |
| Raedsch, R | 1 |
| Daake, H | 1 |
| Eisold, H | 1 |
| Schreiber, H | 1 |
| Gorbauch, T | 1 |
| Kriech, W | 1 |
| Marazova, K | 1 |
| Klouchek, E | 1 |
| Popov, A | 1 |
| Ivanov, CH | 1 |
| Krushkov, I | 1 |
| Tsutsumi, M | 1 |
| Ueshima, Y | 1 |
| Takase, S | 1 |
| Okabe, S | 1 |
| Takagi, K | 1 |
| Igata, H | 1 |
| Kato, S | 1 |
| Shimosako, K | 1 |
| Yamaji, Y | 1 |
| Seiki, M | 1 |
| Murdoch, D | 1 |
| McTavish, D | 1 |
| Walt, RP | 1 |
| Merki, HS | 1 |
| Bender, W | 1 |
| Labs, R | 1 |
| Collins, JD | 1 |
3 reviews available for roxatidine acetate and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
Topics: Animals; Drug Evaluation; Histamine H2 Antagonists; Humans; Peptic Ulcer; Piperidines | 1991 |
Clinical importance of the new H2-antagonists.
Topics: Animals; Famotidine; Histamine H2 Antagonists; Humans; Nizatidine; Peptic Ulcer; Piperidines; Thiazo | 1989 |
Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
Topics: Anti-Ulcer Agents; Cimetidine; Drug Interactions; Histamine H2 Antagonists; Humans; Peptic Ulcer; Pi | 1988 |
4 trials available for roxatidine acetate and Gastroduodenal Ulcer
| Article | Year |
|---|---|
[Effective prevention of indomethacin-induced gastroduodenal mucosal lesions with roxatidine acetate].
Topics: Adult; Cross-Over Studies; Histamine H2 Antagonists; Humans; Indomethacin; Male; Peptic Ulcer; Piper | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
[Treatment of peptic ulcer in internal medicine practice. A multicenter comparative study with roxatidine and cimetidine].
Topics: Adolescent; Adult; Aged; Cimetidine; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Pe | 1993 |
Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
Topics: Cimetidine; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Histamine H | 1989 |
4 other studies available for roxatidine acetate and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Disease Models, Animal; Famotidine; Histamine H2 Antagonists | 2010 |
Gastroprotective effect of MX1 (a novel salt of the active metabolite of roxatidine with a complex of bismuth and citric acid) against stress ulcers in rats.
Topics: Animals; Antacids; Anti-Ulcer Agents; Drug Combinations; Gastric Mucosa; Histamine H2 Antagonists; M | 1997 |
Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Chronic Disease; Creatinine; Half-Life; Hepatit | 2001 |
Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine.
Topics: Acetamides; Administration, Oral; Animals; Dogs; Duodenum; Female; Gastric Acid; Gastric Mucosa; His | 1992 |